# Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance

> **NCT02095145** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 38 (actual)

## Conditions studied

- PSA Level Less Than or Equal to Fifteen
- PSA Level Less Than Ten
- Stage I Prostate Cancer AJCC v7
- Stage II Prostate Cancer AJCC v7
- Stage IIA Prostate Cancer AJCC v7
- Stage IIB Prostate Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **OTHER:** Placebo
- **DRUG:** Pomegranate-Extract Pill

## Key facts

- **NCT ID:** NCT02095145
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-08
- **Primary completion:** 2018-01-23
- **Final completion:** 2019-09-26
- **Target enrollment:** 38 (ACTUAL)
- **Last updated:** 2020-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02095145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02095145, "Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02095145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*